Schizophrenia Drugs Market

SKU: DMPH2901 | Last Updated On: Jul 26 2022 | Available Formats

Schizophrenia Drugs Market Expected to reach a high CAGR of 3% during the forecast period 2022-2029: DataM Intelligence

Schizophrenia Drugs Market is segmented By Drug Class (Second-generation Antipsychotics (Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone), Aristada (Aripiprazole lauroxil), Fanapt (Iloperidone), Saphris (Asenapine), Vraylar (Cariprazine)), Third-generation Antipsychotics (Abilify (Aripiprazole)), Generics, Other), By Route of Administration (Oral Antipsychotics, Injectable Antipsychotics), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Schizophrenia drugs market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 3% during the forecast period (2022-2029).   

Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behaviour that impairs daily functioning, and can be disabling. People with schizophrenia require lifelong treatment.

Market Dynamics

The global schizophrenia drug growth is driven by the increase in the number of patients seeking treatment, and rising demand for improved healthcare infrastructure is expected to drive the market. The schizophrenia market remains replete with strong unmet needs. There is a need for innovation for the treatment of this debilitating disorder.

The increase in the number of patients taking treatment is expected to drive the growth in the forecast period

Subtle changes in cognition and social relationships are expected to precede the actual diagnosis, often by years. According to the World Health Organization 2019 report, the disease affects 20 million people worldwide. Furthermore, this number is likely to continue to increase, along with the ageing population's growth. The increase in the number of patients taking treatment and the rising demand for improved healthcare infrastructure are expected to drive the market. In recent years, the government in several countries has collaborated well with many hospitals across nations to protect people from schizophrenia. The rising burden of the disease and the increasing need to manage it effectively drive the market's growth.

Rising awareness about mental disorders is expected to drive the market growth

The increasing cases of mental disorders such as schizophrenia will uplift the global Schizophrenia Drugs Market shares. The surge in medical interventions for treating major mental disorders will enable growth in the global schizophrenia drugs market during the forecast period. Furthermore, the rising emphasis on mental illness and mental health in emerging nations will boost the global Schizophrenia Drugs Market revenue during the forecast period. Moreover, the increasing efficacy and safety features of treatment for schizophrenia will fuel demand among patients, which will accelerate the growth of the global schizophrenia drugs. Schizophrenia is diagnosed 1.4 times more frequently in males than females, as the onset is earlier in men. The peak age of onset is 20–28 years for males and 25–32 years for females.

Pipeline Analysis

Currently, 20 products are undergoing clinical trials for the treatment of schizophrenia. Some drugs are expected to aim at new molecular targets for treating unmet needs associated with the disorder. Several market players are expected to serve the unmet market needs, identify new targets, and consequentially develop stronger drug pipelines.

Results from clinical trials of these drugs reported positive top-line primary and secondary endpoint data. Apart from the typical serotonin and dopamine receptors, the drugs are expected to provide novel mechanisms for the treatment of schizophrenia.

Major side effects of drugs are likely to hinder the market growth

However, side effects include bladder disturbances, dermatologic allergic reactions, increased photosensitivity, inhibition of ejaculation, blurred vision, skin pigmentation, ocular opacities, mild fever, nasal congestion, increase in appetite, weight gain, engorgement of the breast with lactation, and menstrual irregularity in female patients. These factors are restricting the growth of the market in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic may have a profound effect on mental health. Those with schizophrenia will affect most. Patients are at higher risk of getting the COVID-19 virus; if being contaminated, what is the expected mortality rate in this patient group? What is the likelihood of suffering from a psychotic relapse due to the situation? According to their findings, schizophrenia patients are at greater infection risk due to their difficulties in following safety procedures. However, schizophrenia patients have deficits in applying adequate hygiene practices mainly because of impaired judgment and self-care.

Approximately 70% of schizophrenia patients suffer from one or more concomitant diseases, and 50-90% of them are regular smokers. Moreover, higher odds of pneumonia and mortality due to immunodeficiency have been suggested in several articles, alongside impaired lung function indications. Regarding the chance of relapse, the COVID-19 can indeed lead indirectly to relapse. These factors are driving the growth of the market in the forecast period.

Schizophrenia Drugs Market Scope



Market CAGR


Segments Covered

By Drug Class, By Route of Administration, By Distribution Channel,  and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Get Our Sample Brochure

Segment Analysis

The second-generation antipsychotics segment is expected to grow at the fastest CAGR during the forecast period  (2021-2028)  

The usual first-line treatment for schizophrenia is an antipsychotic medication. One of the commonly preferred medications is risperidone, also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Risperidone rebalances dopamine and serotonin to improve thinking, mood, and behaviour. It is expected to help in curing some or all of the symptoms of schizophrenia. Moreover, in the United States, the Food and Drug Administration (FDA) approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance (long-term) treatment of the bipolar disorder, and irritability associated with autistic disorders. There are several second-generation drugs available in the market, which are commonly proposed by doctors/physicians. The government's continuous support of private and public healthcare companies also boosts companies' growth in this segment. Therefore, considering the aforementioned reasons, the market for second-generation antipsychotics is likely to grow steadily over the forecast period.

The hospital pharmacy is expected to dominate the schizophrenia drugs during the forecast period

The hospital pharmacies held the largest share in the schizophrenia drugs market. This is mainly due to the increasing number of patients suffering from conditions treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals and adequate reimbursement policies are also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global schizophrenia drugs 

North America region is dominating the global schizophrenia drugs accounted for the largest market share in 2020. The United States accounted for the largest market share in the NorthAmerica region. A major section of the population is approaching such medications therapies, primarily due to hectic lifestyles. Moreover, the country offers highly advanced medical care for early treatment capabilities and government involvement in increasing healthcare expenditure. This factor is driving the market growth in the forecast period.

Competitive Landscape

The schizophrenia drugs market is moderately competitive with the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan, and Pfizer. Johnson & Johnson, Otsuka, and Lundbeck among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of schizophrenia drugs globally.    

Schizophrenia Drugs Market Key Companies to Watch

Pfizer Inc. 

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Trending Topics

Epilepsy Drugs Market

Acute Coronary Syndrome Market

Asthma and COPD Drug Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!